Top

Published in:

Open Access 01-09-2011 | Review Article

Clinical and Experimental Applications of Sodium Phenylbutyrate

Authors: Mr Tommaso Iannitti, Beniamino Palmieri

Published in: Drugs in R&D | Issue 3/2011

Abstract

Histone acetyltransferase and histone deacetylase are enzymes responsible for histone acetylation and deacetylation, respectively, in which the histones are acetylated and deacetylated on lysine residues in the N-terminal tail and on the surface of the nucleosome core. These processes are considered the most important epigenetic mechanisms for remodeling the chromatin structure and controlling the gene expression. Histone acetylation is associated with gene activation. Sodium phenylbutyrate is a histone deacetylase inhibitor that has been approved for treatement of urea cycle disorders and is under investigation in cancer, hemoglobinopathies, motor neuron diseases, and cystic fibrosis clinical trials. Due to its characteristics, not only of histone deacetylase inhibitor, but also of ammonia sink and chemical chaperone, the interest towards this molecule is growing worldwide. This review aims to update the current literature, involving the use of sodium phenylbutyrate in experimental studies and clinical trials.

14-3-3 proteins play an important role in cancer biology by interfering with intracellular signaling pathways and cell cycle checkpoints,and in particular the 14-3-3σ isoform acts as a tumor suppressor and is often inactivated during the tumor development.

Waddington CH. The epigenotype. Endeavour 1942; 1: 18

Waddington CH. Towards a theoretical biology: the basic ideas of biology. Edinburgh: Edinburgh University Press, 1968: 1–32

Suzuki T, Miyata N. Epigenetic control using natural products and synthetic molecules. Curr Med Chem 2006; 13 (8): 935–58PubMedCrossRef

Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005 Jan; 40 (1): 1–13PubMedCrossRef

Smith BC, Denu JM. Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta 2009 Jan; 1789 (1): 45–57PubMedCrossRef

Gray SG, Ekström TJ. The human histone deacetylase family. Exp Cell Res 2001 Jan 15; 262 (2): 75–83PubMedCrossRef

Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000 Jan 6; 403 (6765): 41–5PubMedCrossRef

Chang KT, Min KT. Regulation of lifespan by histone deacetylase. Ageing Res Rev 2002 Jun; 1 (3): 313–26PubMedCrossRef

Grayson DR, Kundakovic M, Sharma RP. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol 2010 Feb; 77 (2): 126–35PubMedCrossRef

10.

Egler V, Korur S, Failly M, et al. Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clin Cancer Res 2008 May 15; 14 (10): 3132–40PubMedCrossRef

11.

Spira AI, Carducci MA. Differentiation therapy. Curr Opin Pharmacol 2003; 3: 338–43PubMedCrossRef

12.

Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res 1991; 29: 147–50PubMedCrossRef

13.

Feillet F, Leonard JV. Alternative pathway therapy for urea cycle disorders. J Inherit Metab Dis 1998; 21 Suppl. 1: 101–11

14.

Carducci MA, Nelson JB, Chan-Tack KM, et al. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 1996; 2: 379–87PubMed

15.

Zeitlin PL, Diener-West M, Rubenstein RC, et al. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 2002 Jul; 6 (1): 119–26PubMedCrossRef

16.

Gilbert J, Baker SD, Bowling MK, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001; 7: 2292–300PubMed

17.

Kemp S, Wei H-M, Lu J-F, et al. Gene redundancy of pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat Med 1998; 4: 1261–8PubMedCrossRef

18.

Berg S, Serabe B, Aleksic A, et al. Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate. Cancer Chemother Pharmacol 2001; 47: 385–90PubMedCrossRef

19.

Maestri NE, Brusilow SW, Clissold DB, et al. Longterm treatment of a girl with ornithine transcarbamilase deficiency. N Engl J Med 1996; 335: 855–9PubMedCrossRef

20.

Redonnet-Vernhet I, Rouanet F, Pedespan JM, et al. A successful pregnancy in a heterozygote for OTC deficiency treated with sodium phenylbutyrate. Neurology 2000; 54: 1008PubMedCrossRef

21.

Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92: 1210–6PubMedCrossRef

22.

Svechnikova I, Almqvist PM, Ekström TJ. HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin. Int J Oncol 2008 Apr; 32 (4): 821–7PubMed

23.

Dasgupta S, Zhou Y, Jana M, et al. Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps. J Immunol 2003 Apr 1; 170 (7): 3874–82PubMed

24.

Qi X, Hosoi T, Okuma Y, et al. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol Pharmacol 2004 Oct; 66 (4): 899–908PubMedCrossRef

25.

Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008 Oct; 7 (10): 854–68PubMedCrossRef

26.

Chiurazzi P, Neri G. Pharmacological reactivation of inactive genes: the fragile X experience. Brain Res Bull 2001 Oct–Nov 1; 56 (3–4): 383–7PubMedCrossRef

27.

Chiurazzi P, Pomponi MG, Willemsen R, et al. In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum Mol Genet 1998; 7: 109–13PubMedCrossRef

28.

Yoshida M, Furumai R, Nishiyama M, et al. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 2001; 48 Suppl. 1: S20–6PubMedCrossRef

29.

Nakano K, Mizuno T, Sowa Y, et al. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 1997; 272: 22199–206PubMedCrossRef

30.

Huang L, Sowa Y, Sakai T, et al. Activation of the p21WAF1/ CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000; 19: 5712–9PubMedCrossRef

31.

Kim YH, Park JW, Lee JY, et al. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 2004; 25: 1813–20PubMedCrossRef

32.

Feinman R, Clarke KO, Harrison LE. Phenylbutyrate-induced apoptosis is associated with inactivation of NF-kappaB IN HT-29 colon cancer cells. Cancer Chemother Pharmacol 2002; 49: 27–34PubMedCrossRef

33.

Svechnikova I, Gray SG, Kundrotiene J, et al. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol 2003; 22: 579–88PubMed

34.

Yokota N, Mainprize TG, Taylor MD, et al. Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene 2004; 23: 3444–53PubMedCrossRef

35.

Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45: 495–528PubMedCrossRef

36.

Bhalla K, List A. Histone deacetylase inhibitors in myelodysplastic syndrome. Best Pract Res Clin Haematol 2004; 17: 595–611PubMed

37.

Phuphanich S, Baker SD, Grossman SA, et al. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neurooncol 2005; 7: 177–82

38.

Ryu H, Smith K, Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of antiapoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005; 93: 1087–98PubMedCrossRef

39.

Qi X, Hosoi T, Okuma Y, et al. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol Pharmacol 2004; 66: 899–908PubMedCrossRef

40.

Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137–40PubMedCrossRef

41.

Liu XL, Done SC, Yan K, et al. Defective trafficking of nephrin missense mutants rescued by a chemical chaperone. J Am Soc Nephrol 2004; 15: 1731–8PubMedCrossRef

42.

Scaglia F, Carter S, O’Brien WE, et al. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol Genet Metab 2004; 81: S79–85PubMedCrossRef

43.

Maestri NE, Brusilow SW, Clissold DB, et al. Long-term treatment of girls with ornithine, transcarbamylase deficiency. N Engl J Med 1996; 335: 855–9PubMedCrossRef

44.

Peart MJ, Tainton KM, Ruefli AA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003; 63: 4460–71PubMed

45.

Blagosklonny MV, Robey R, Sackett DL, et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002; 1: 937–41PubMed

46.

Ishiguro K, Sartorelli AC. Activation of transiently transfected reporter genes in 3T3 Swiss cells by the inducers of differentiation/apoptosis-dimethylsulfoxide, hexamethylene bisacetamide and trichostatin A. Eur J Biochem 2004; 271: 2379–90PubMedCrossRef

47.

Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 2004; 10: 2289–98PubMedCrossRef

48.

Yamano T, Ura K, Morishita R, et al. Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase. Mol Ther 2000; 1: 574–80PubMedCrossRef

49.

Takimoto R, Kato J, Terui T, et al. Augmentation of antitumor effects of p53 gene therapy by combination with HDAC inhibitor. Cancer Biol Ther 2005; 4: 421–8PubMedCrossRef

50.

Lin J, Gilbert J, Rudek MA, et al. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res 2009 Oct 1; 15 (19): 6241–9PubMedCrossRef

51.

Piscitelli SC, Thibault A, Figg WD, et al. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J Clin Pharmacol 1995; 35: 368–73PubMed

52.

Liu L, Hudgins WR, Miller AC, et al. Transcriptional upregulation of TGF-alpha by phenylactate and phenylbutyrate is associated with differentiation of human cells. Cytokine 1995; 7: 449–56PubMedCrossRef

53.

Zhang X, Wei L, Yang Y, et al. Sodium 4-phenylbutyrate induces apoptosis of human lung carcinoma cells through activating JNK pathway. J Cell Biochem 2004; 93 (4): 819–29PubMedCrossRef

54.

Carducci MA, Gilbert J, Bowling MK, et al. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 2001 Oct; 7: 3047–55PubMed

55.

Camacho LH, Olson J, Tong WP, et al. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs 2007; 25: 131–8PubMedCrossRef

56.

Gore SD, Weng LJ, Figg WD, et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2002 Apr; 8 (4): 963–70PubMed

57.

Christov K, Grubbs CJ, Shilkaitis A, et al. Short-term modulation of cell proliferation and apoptosis and preventive/ therapeutic efficacy of various agents in a mammary cancer model. Clin Cancer Res 2007 Sep 15; 13 (18 Pt 1): 5488–96CrossRef

58.

Daosukho C, Chen Y, Noel T, et al. Phenylbutyrate, a histone deacetylase inhibitor, protects against adriamycin-induced cardiac injury. Free Radic Biol Med 2007 Jun 15; 42 (12): 1818–25PubMedCrossRef

59.

DiGiuseppe JA, Weng L-J, Yu KH, et al. Phenylbutyrateinduced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia (Baltimore) 1999; 13: 1243–53CrossRef

60.

Gore SD, Samid D, Weng L-J. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Canc Res 1997; 3: 1755–62

61.

Yu KH, Weng L-J, Fu S, et al. Augmentation of phenylbutyrate- induced differentiation of myeloid leukemia cells using all trans-retinoic acid. Leukemia (Baltimore) 1999; 13: 1258–65CrossRef

62.

Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999; 94: 417–28PubMed

63.

Ryningen A, Stapnes C, Bruserud Ø. Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting. Leukemia Res 2007; 31: 1303–13CrossRef

64.

Burkitt K, Ljungman M. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin. Mol Cancer 2008; 7: 24PubMedCrossRef

65.

Bandres E, Agirre X, Bitarte N, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009; 125: 2737–43PubMedCrossRef

66.

Hurtubise A, Bernstein ML, Momparler RL. Preclinical evaluation of the antineoplastic action of 5-aza-2’-deoxycytidine and different histone deacetylase inhibitors on human Ewing’s sarcoma cells. Cancer Cell Int 2008 Nov 17; 8: 16CrossRef

67.

Vine AL, Bertram JS. Cancer chemoprevention by connexins. Cancer Metastasis Rev 2002; 21: 199–216PubMedCrossRef

68.

Seo MS, Park JS, Yang SR, et al. Expression ofMAP kinases and connexins in the differentiation of rat mammary epithelial cells. J Vet Med Sci 2006 Jun; 68 (6): 567–71PubMedCrossRef

69.

Yamasaki H, Naus CC. Role of connexin genes in growth control. Carcinogenesis 1996 Jun; 17 (6): 1199–213PubMedCrossRef

70.

Lee SW, Tomasetto C, Paul D, et al. Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumor cell lines. J Cell Biol 1992; 118: 1213–21PubMedCrossRef

71.

Pelin K, Hirvonen A, Linnainmaa K. Expression of cell adhesion molecules and connexins in gap junctional intercellular communication deficient human mesothelioma tumour cell lines and communication competent primary mesothelial cells. Carcinogenesis 1994; 15: 2673–5PubMedCrossRef

72.

Zhang ZQ, Zhang W, Wang NQ, et al. Suppression of tumorigenicity of human lung carcinoma cells after transfection with connexin43. Carcinogenesis 1998; 19: 1889–94PubMedCrossRef

73.

Mehta PP, Perez-Stable C, Nadji M, et al. Suppression of human prostate cancer cell growth by forced expression of connexin genes. Dev Genet 1999; 24: 91–110PubMedCrossRef

74.

Hattori Y, Fukushima M, Maitani Y. Non-viral delivery of the connexin 43 gene with histone deacetylase inhibitor to human nasopharyngeal tumor cells enhances gene expression and inhibits in vivo tumor growth. Int J Oncol 2007; 30: 1427–39PubMed

75.

Bueno MJ, Pérez de Castro I, Gómez de Cedrón M, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008 Jun; 13 (6): 496–506PubMedCrossRef

76.

Ammerpohl O, Trauzold A, Schniewind B, et al. Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br J Cancer 2007; 96: 73–81PubMedCrossRef

77.

Phillips JA, Griffin BE. Pilot study of sodium phenylbutyrate as adjuvant in cyclophosphamide-resistant endemic Burkitt’s lymphoma. Trans R Soc Trop Med Hyg 2007 Dec; 101 (12): 1265–9PubMedCrossRef

78.

Hanada S, Harada M, Kumemura H, et al. Oxidative stress induces the endoplasmic reticulum stress and facilitates inclusion formation in cultured cells. J Hepatol 2007 Jul; 47 (1): 93–102PubMedCrossRef

79.

Egger G, Aparicio AM, Escobar SG, et al. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2’-deoxycytidine treatment. Cancer Res 2007 Jan 1; 67 (1): 346–53PubMedCrossRef

80.

Gray SG, Al-Sarraf N, Baird AM, et al. Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. Eur J Cancer 2009 Nov; 45 (17): 3087–97PubMedCrossRef

81.

Hauswald S, Duque-Afonso J, Wagner MM, et al. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res 2009 Jun 1; 15 (11): 3705–15PubMedCrossRef

82.

Svechnikova I, Ammerpohl O, Ekström TJ. p21waf1/Cip1 partially mediates apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2007 Mar 9; 354 (2): 466–71PubMedCrossRef

83.

Verheul HM, Qian DZ, Carducci MA, et al. Sequencedependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemother Pharmacol 2007 Aug; 60 (3): 329–39PubMedCrossRef

84.

Lopez CA, Feng FY, Herman JM, et al. Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation. Int J Radiat Oncol Biol Phys 2007 Sep 1; 69 (1): 214–20PubMedCrossRef

85.

Schultz J, Ibrahim SM, Vera J, et al. 14-3-3sigma gene silencing during melanoma progression and its role in cell cycle control and cellular senescence. Mol Cancer 2009 Jul 30; 8: 53PubMedCrossRef

86.

Merzvinskyte R, Treigyte G, Savickiene J, et al. Effects of histone deacetylase inhibitors, sodium phenyl butyrate and vitaminB3, incombinationwith retinoic acidongranulocytic differentiation of human promyelocytic leukemia HL-60 cells. Ann N Y Acad Sci 2006 Dec; 1091: 356–67PubMedCrossRef

87.

Denu JM. Vitamin B3 and sirtuin function. Trends Biochem Sci 2005 Sep; 30 (9): 479–83PubMedCrossRef

88.

Wang CT, Meng M, Zhang JC, et al. Growth inhibition and gene induction in human hepatocellular carcinoma cell exposed to sodium 4-phenylbutanoate. Chin Med J (Engl) 2008 Sep 5; 121 (17): 1707–11

89.

Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007 Jan; 24 (1): CD001447

90.

Dion PA, Daoud H, Rouleau GA. Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat Rev Genet 2009 Nov; 10 (11): 769–82PubMedCrossRef

91.

Darras BT, Kang PB. Spinal muscular atrophy. Curr Opin Ped 2007; 19: 675–9CrossRef

92.

Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008 Jun 21; 371 (9630): 2120–33PubMedCrossRef

93.

Zerres K, Rudnick-Schoneborn S. Natural history in proximal spinal muscular atrophy. Arch Neurol 1995; 52: 518–23PubMedCrossRef

94.

Pazin MJ, Kadonaga JT. What’s up and down with histone deacetylation and transcription? Cell 1997; 89: 325–8PubMedCrossRef

95.

Andreassi C, Angelozzi C, Tiziano FD, et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004; 12: 59–65PubMedCrossRef

96.

Hauke J, Riessland M, Lunke S, et al. Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum Mol Genet 2009 Jan 15; 18 (2): 304–17PubMedCrossRef

97.

Chang JG, Hsieh-Li HM, Jong YJ, et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001; 98: 9808–13PubMedCrossRef

98.

Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001 May 31; 344 (22): 1688–700PubMedCrossRef

99.

Chiò A, Logroscino G, Hardiman O, et al., Eurals Consortium. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009 Oct–Dec; 10 (5–6): 310–23PubMedCrossRef

100.

Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 2009 Nov; 8 (11): 1056–72PubMedCrossRef

101.

Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994 Mar 3; 330 (9): 585–91PubMedCrossRef

102.

Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 2003 Sep; 4 (3): 191–206PubMedCrossRef

103.

Armon C. Motor neuron disease. In: Gorelick PB, Alter M, editors. Handbook of neuroepidemiology. New York: Marcel Dekker, 1994: 407–54

104.

Brown Jr RH, Robberecht W. Amyotrophic lateral sclerosis: pathogenesis. Semin Neurol 2001 Jun; 21 (2): 131–9PubMedCrossRef

105.

Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994 Jun 17; 264 (5166): 1772–5. Erratum in: Science 1995 Jul 14; 269 (5221): 149PubMedCrossRef

106.

Bruijn LI, Beal MF, Becher MW, et al. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci U S A 1997 Jul 8; 94 (14): 7606–11PubMedCrossRef

107.

Bruijn LI, Becher MW, Lee MK, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997 Feb; 18 (2): 327–38PubMedCrossRef

108.

Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001 Nov; 2 (11): 806–19PubMedCrossRef

109.

Kostic V, Jackson-Lewis V, de Bilbao F, et al. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997 Jul 25; 277 (5325): 559–62PubMedCrossRef

110.

Wakabayashi K, Saito H, Ebinuma H, et al. Bcl-2 related proteins are dramatically induced at the early stage of differentiation in human liver cancer cells by a histone deacetylase inhibitor projecting an anti-apoptotic role during this period. Oncol Rep 2000 Mar–Apr; 7 (2): 285–8PubMed

111.

Vukosavic S, Stefanis L, Jackson-Lewis V, et al. Delaying caspase activation by Bcl-2: a clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2000 Dec 15; 20 (24): 9119–25PubMed

112.

Petri S, Kiaei M, Kipiani K, et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2006 Apr; 22 (1): 40–9PubMedCrossRef

113.

Del Signore SJ, Amante DJ, Kim J, et al. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph Lateral Scler 2009 Apr; 10 (2): 85–94PubMedCrossRef

114.

Cudkowicz ME, Andres PL, Macdonald SA, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 2009 Apr; 10 (2): 99–106PubMedCrossRef

115.

Osborne NN, Casson RJ, Wood JP, et al. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res 2004; 23: 91e147CrossRef

116.

Lagrèze WA, Knörle R, Bach M, et al. Memantine is neuroprotective in a ratmodel of pressure-induced retinal ischemia. Invest Ophthalmol Vis Sci 1998 May; 39 (6): 1063–6PubMed

117.

Lagrèze WA, Knörle R, Bach M, et al. Retinal ganglion cell dysfunction induced by hypoxia and glutamate: potential neuroprotective effects of beta-blockers. Surv Ophthalmol 1999; 43: 162e170

118.

Jeng YY, Lin NT, Chang PH, et al. Retinal ischemic injury rescued by sodium 4-phenylbutyrate in a rat model. Exp Eye Res 2007 Mar; 84 (3): 486–92PubMedCrossRef

119.

Vilatoba M, Eckstein C, Bilbao G, et al. Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum-stress mediated apoptosis. Surgery 2005 Aug; 138 (2): 342–51PubMedCrossRef

120.

Leonard JV, Morris AAM. Urea cycle disorders. Semin Neonatol 2002; 7: 27–35PubMedCrossRef

121.

Batshaw ML, Berry GT. Use of citrulline as a diagnostic marker in the prospective treatment of urea cycle disorders. J Pediatr 1991; 118: 914–7PubMedCrossRef

122.

Brusilow SW, Finkelstein JE. Restoration of nitrogen homeostasis in a man with ornithine transcarbamylase deficiency. Metabolism 1993; 42: 1336–9PubMedCrossRef

123.

Leonard JV. Disorders of the urea cycle and related enzymes. 4th rev ed. Berlin: Springer, 2006

124.

Gordon N. Ornithine transcarbamylase deficiency: a urea cycle defect. Eur J Paed Neurol 2003; 7: 115–21CrossRef

125.

Praphanphoj V, Boyadjiev SA, Waber LJ, et al. Three cases of intravenous sodium benzoate and sodium phenylbutyrate toxicity occurring in the treatment of acute hyperammonaemia. J Inherit Metab Dis 2000; 23: 129–36PubMedCrossRef

126.

Wilcken B. Problems in the management of urea cycle disorders. Mol Genet Metab 2004 Apr; 81 Suppl. 1: S86–91PubMedCrossRef

127.

Schultz REH, Salo MK. Under recognition of late onset ornithine transcarbamylase deficiency. Arch Dis Child 2000; 82: 390–1PubMedCrossRef

128.

Nicolaides P, Liebsch D, Dale N, et al. Neurological outcome of patients with ornithine carbamoyltransferase deficiency. Arch Dis Child 2002; 86: 54–6PubMedCrossRef

129.

Schwab S, Scharz S, Mayatepek E, et al. Recurrent brain edema in ornithine transcarbamylase deficiency. J Neurol 1999; 246: 609–11PubMedCrossRef

130.

Lee J-Y, Chang S-E, Sub C-W, et al. A case of acrodermatitis enteropathica-like dermatosis caused by ornithine transcarbamylase deficiency. J Am Acad Dermatol 2002; 46: 965–7PubMedCrossRef

131.

Legras A, Labarthe F, Maillot F, et al. Late diagnosis of ornithine transcarbamylase defect in three related female patients: polymorphic presentations. Crit Care Med 2002; 30: 241–4PubMedCrossRef

132.

Anadiotis G, Ierardi-Curto L, Kaplan PD, et al. Ornithine transcarbamylase deficiency and pancreatitis. J Pediatr 2001; 138: 123–4PubMedCrossRef

133.

Winichagoon P, Fucharoen S, Chen P, et al. Genetic factors affecting clinical severity in β-thalassemia syndromes. J Ped Hematol Oncol 2000 Nov/Dec; 22 (6): 573–80CrossRef

134.

Dover GJ. Hemoglobin switching protocols in thalassemia: experience with sodium phenylbutyrate and hydroxyurea. Ann N Y Acad Sci 1998 Jun 30; 850: 80–6PubMedCrossRef

135.

Orkin SH, Swan D, Leder P. Differential expression of α- and β-globin genes during differentiation of cultured erythroleukemic cells. J Biol Chem 1975; 250: 8753PubMed

136.

Anderson LC, Jokinen M, Gahmberg CG. Induction of erythroid differentiation in the human leukemia cell line K562. Nature 1979; 278: 364CrossRef

137.

Samid D, Shack S, Sherman LT. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res 1992; 52: 1988PubMed

138.

Perrine SP, Miller BA, Faller DV, et al. Sodium butyrate enhances fetal globin expression in erythroid progenitors of patients with HbSS and β-thalassemia. Blood 1989; 74: 454PubMed

139.

Fibach E, Prasanna P, Rodgers GP, et al. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal blood donors and patients with sickle cell anemia and β-thalassemia. Blood 1993; 82: 2203PubMed

140.

Stamatoyannopoulos G, Nakamoto B, Josephson B, et al. Acetate, a product of butyrate catabolism, stimulates β-globin expression in adult cells in vivo and in culture [abstract]. Blood 1993; 82: 313a

141.

Ginder GD, Whitters MJ, Pohlman JK. Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate. Proc Natl Acad Sci USA 1984; 81: 3954PubMedCrossRef

142.

Perrine SP, Rudolph A, Faller DV, et al. Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. Proc Natl Acad Sci U S A 1988 Nov; 85 (22): 8540–2PubMedCrossRef

143.

Constantoulakis P, Papayannopoulou TH, Stamatoyannopoulos G. Alpha-amino-N-butyric acid stimulates fetal hemoglobin in the adult. Blood 1988; 72: 1961. 21

144.

Constantoulakis P, Knitter G, Stamatoyannopoulos G. On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatment with 5-azaC and Ara C. Blood 1989; 74: 1963. 22

145.

Blau CA, Constantoulakis P, Shaw CM, et al. Fetal hemoglobin induction with butyric acid: efficacy and toxicity. Blood 1993; 81: 529PubMed

146.

Dover GJ, Brusilow SW, Samid D. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate [letter 29]. N Engl J Med 1992; 327: 569PubMed

147.

Dover GJ, Brusilow SW, Charache S. Induction of HbF production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994; 84: 339PubMed

148.

Perrine SP. Fetal globin stimulant therapies in the betahemoglobinopathies: principles and current potential. Pediatr Ann 2008 May; 37 (5): 339–46PubMed

149.

Tsui LC. Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Hum Mutat 1992; 1: 197–203PubMedCrossRef

150.

Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066–73PubMedCrossRef

151.

Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995; 83: 121–7PubMedCrossRef

152.

Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in delta F508- homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998 Feb; 157 (2): 484–90PubMed

153.

Lim M, McKenzie K, Floyd AD, et al. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol 2004 Sep; 31 (3): 351–7PubMedCrossRef

154.

Cheng SH, Fang SL, Zabner J, et al. Functional activation of the cystic fibrosis trafficking mutant delta F508-CFTR by overexpression. Am J Physiol 1995; 268: L615–24PubMed

155.

Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997 Nov 15; 100 (10): 2457–65PubMedCrossRef

156.

Lim M, Zeitlin PL. Therapeutic strategies to correct malfunction of CFTR. Paediatr Respir Rev 2001 Jun; 2 (2): 159–64PubMedCrossRef

157.

Andersson C, Servetnyk Z, Roomans GM. Activation of CFTR by genistein in human airway epithelial cell lines. Biochem Biophys Res Commun 2003 Aug 29; 308 (3): 518–22PubMedCrossRef

158.

Andersson C, Roomans GM. Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX. Eur Respir J 2000 May; 15 (5): 937–41PubMedCrossRef

159.

Nguyen TD, Kim US, Perrine SP. Novel short chain fatty acids restore chloride secretion in cystic fibrosis. Biochem Biophys Res Commun 2006 Mar 31; 342 (1): 245–52PubMedCrossRef

160.

Singh OV, Pollard HB, Zeitlin PL. Chemical rescue of deltaF508-CFTR mimics genetic repair in cystic fibrosis bronchial epithelial cells. Mol Cell Proteomics 2008 Jun; 7 (6): 1099–110PubMedCrossRef

161.

Singh OV, Vij N, Mogayzel Jr PJ, et al. Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells. J Proteome Res 2006 Mar; 5 (3): 562–71PubMedCrossRef

162.

Rubenstein RC, Lyons BM. Sodium 4-phenylbutyrate downregulates HSC70 expression by facilitating mRNA degradation. Am J Physiol Lung Cell Mol Physiol 2001 Jul; 281 (1): L43–51PubMed

163.

Rubenstein RC, Zeitlin PL. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am J Physiol Cell Physiol 2000 Feb; 278 (2): C259–67PubMed

164.

Linsdell P. Direct block of the cystic fibrosis transmembrane conductance regulator Cl(−) channel by butyrate and phenylbutyrate. Eur J Pharmacol 2001 Jan 12; 411 (3): 255–60PubMedCrossRef

165.

Prulière-Escabasse V, Planès C, Escudier E, et al. Modulation of epithelial sodium channel trafficking and function by sodium 4-phenylbutyrate in human nasal epithelial cells. J Biol Chem 2007 Nov 23; 282 (47): 34048–57PubMedCrossRef

166.

Ebbel EN, Leymarie N, Schiavo S, et al. Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/ electrochemical array/mass spectrometry and off-line tandem mass spectrometry. Anal Biochem 2010 Apr 15; 399 (2): 152–61PubMedCrossRef

167.

Atwal RS, Truant R. A stress sensitive ER membraneassociation domain in Huntington protein defines a potential role for Huntington in the regulation of autophagy. Autophagy 2008 Jan 1; 4 (1): 91–3PubMed

168.

Marambaud P, Dreses-Werringloer U, Vingtdeux V. Calcium signaling in neurodegeneration. Mol Neurodegener 2009 May 6; 4: 20PubMedCrossRef

169.

Gardian G, Browne SE, Choi DK, et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington’s disease. J Biol Chem 2005 Jan 7; 280 (1): 556–63PubMed

170.

Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice. J Neurosci 2003 Oct 15; 23 (28): 9418–27PubMed

171.

Borovecki F, Lovrecic L, Zhou J, et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington’s disease. Proc Natl Acad Sci U S A 2005 Aug 2; 102 (31): 11023–8PubMedCrossRef

172.

Hogarth P, Lovrecic L, Krainc D. Sodium phenylbutyrate in Huntington’s disease: a dose-finding study. Mov Disord 2007 Oct 15; 22 (13): 1962–4PubMedCrossRef

173.

Van den Berghe PV, Stapelbroek JM, Krieger E, et al. Reduced expression of ATP7B affected by Wilson diseasecausing mutations is rescued by pharmacological folding chaperones 4-phenylbutyrate and curcumin. Hepatology 2009 Dec; 50 (6): 1783–95PubMedCrossRef

174.

Van der Velden LM, Stapelbroek JM, Krieger E, et al. Folding defects in P-type ATP 8B1 associated with hereditary cholestasis are ameliorated by 4-phenylbutyrate. Hepatology 2010 Jan; 51 (1): 286–96PubMedCrossRef

175.

Kubota K, Niinuma Y, Kaneko M, et al. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J Neurochem 2006 Jun; 97 (5): 1259–68PubMedCrossRef

176.

Ricobaraza A, Cuadrado-Tejedor M, Pérez-Mediavilla A, et al. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer’s disease mouse model. Neuropsychopharmacology 2009 Jun; 34 (7): 1721–32. Epub 2009 Jan 14PubMedCrossRef

177.

Brunetti-Pierri N, Lanpher B, Erez A, et al. Phenylbutyrate therapy for maple syrup urine disease. Hum Mol Genet 2011 Feb 15; 20 (4): 631–40PubMedCrossRef

178.

Xiao C, Giacca A, Lewis GF. Sodium phenylbutyrate, a drug with known capacity to reduce endoplasmic reticulum stress, partially alleviates lipid-induced insulin resistance and beta-cell dysfunction in humans. Diabetes 2011 Mar; 60 (3): 918–24PubMedCrossRef

Title: Clinical and Experimental Applications of Sodium Phenylbutyrate
Authors: Mr Tommaso Iannitti
Beniamino Palmieri
Publication date: 01-09-2011
Publisher: Springer International Publishing
Published in: Drugs in R&D / Issue 3/2011
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI: https://doi.org/10.2165/11591280-000000000-00000

2024 ASCO Annual Meeting

Springer Medicine

Clinical and Experimental Applications of Sodium Phenylbutyrate

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Seated Cuff Blood Pressure-Lowering Efficacy of an Olmesartan Medoxomil-Based Treatment Regimen in Patients with Type 2 Diabetes Mellitus

Impact of Intravenous Naltrexone on Intravenous Morphine-Induced High, Drug Liking, and Euphoric Effects in Experienced, Nondependent Male Opioid Users

Impact of Respiratory Syncytial Virus

Short-Term Acetylsalicylic Acid (Aspirin) Use for Pain, Fever, or Colds —Gastrointestinal Adverse Effects